# Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer

> **NCT07107217** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Doxorubicin +cyclophosphamide+ filgrastimum
- **DRUG:** carboplatin + paclitaxel (CP)

## Key facts

- **NCT ID:** NCT07107217
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07107217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07107217, "Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07107217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*